中草藥O007和Thymoquinoe結合對於三陰性乳腺癌細胞的抑制作用

Combined Inhibitory Effect of Chinese Herbal Medicine O007 and Thymoquinone in Triple-Negative Breast Cancer Cells

顏國城(Kuo-Cheng Yen)

指導教授 ： 蕭明文 ； 黃俊銘

中山醫學大學/健康管理學院/應用化學系碩士班/碩士(2016年)

摘要

乳癌是癌症婦女中最常見的類型，發病率在年齡在45-69中最高。根據國家衛福部收集的資料統計，每年大約有10000確診和2000人死亡，相當於確診的29人中有6人死亡。因此，如何治療乳癌是重要的議題。而根據實驗室以前對O007的研究，我們已經發現水萃物對乳癌細胞有抑制的作用。在這項研究中，我們使用O007和百里醌（TQ）來看細胞變化。
通過MTT的方法測試，我們發現O007和TQ的有效濃度分別為400휇g/mL和8휇M以及400휇g/mL和10휇M，在這濃度下我們發現，與控制組相比的話具有加乘作用，然而在這兩種化合物單獨作用下對癌細胞無顯著的抑制作用。
此外根據Flow的數據，與單一藥物相比之下，兩種藥物的混合可以使sub-G1明顯的增加。
因此，我們的結論是O007和TQ之間的具有顯著的加乘效應。在這項研究中的下一部分，我們將使用western來確定此效果的機制。

關鍵字

中草藥 ； 百里醌乳癌

並列摘要

Breast cancer is the most common type of cancer in women today, with the highest incidence rate in the age group of 45-69. According to the statistics collected by Ministry of Health and Welfare and the National Health Department, there are approximately 10000 diagnoses and 2000 deaths every year, equivalent to 29 diagnoses and 6 deaths per day on an average basis. Therefore, it is important to treat breast cancer. From our previous research on O007, we have discovered an aqueous extract has an inhibitory effect on breast cancer cells. In this study we use O007 and Thymoquinone(TQ) to see cellular changes.
By using the MTT assay, we have discovered that at concentrations of 400휇g/mL and 8휇M as well as 400휇g/mL and 10휇M of O007 and TQ respectively, a synergistic effect was observed, as compared to the untreated group. However, when the two chemicals are administered independently, there is no significant inhibitory effects on cancer cell growth. Moreover, according to the flow cytometry analysis, the rate of Sub-G1 phase was increased in the O007- and TQ -cotreated cells, as compared to the cells treated with control group or single drug only group. Therefore, we conclude that there is a significant synergistic effect between O007 and TQ. In the next part of this study we will use western blot to determine the mechanism of this effect.

並列關鍵字

O007 ； Thymoquinone ； breast cancer

參考文獻

Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012 Apr 4;486(7403):395-9. doi: 10.1038/nature10933

Foulkes WD1, Smith IE, Reis-Filho JS. Triple-negative breast cancer N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389.

Dent R1, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.

Miski, M., et al., Antibacterial activity studies of flavonoids from Salvia palaestina. J Nat Prod, 1983. 46(6): p. 874-5.

方博正, 台灣產生藥之抗氧化及抗皰疹病毒活性資源開發研究, in 天然藥物研究所. 2001, 高雄醫學大學: 高雄.